CA2760778A1 - Composes heteroaryle en tant qu'inhibiteurs des pikk - Google Patents

Composes heteroaryle en tant qu'inhibiteurs des pikk Download PDF

Info

Publication number
CA2760778A1
CA2760778A1 CA2760778A CA2760778A CA2760778A1 CA 2760778 A1 CA2760778 A1 CA 2760778A1 CA 2760778 A CA2760778 A CA 2760778A CA 2760778 A CA2760778 A CA 2760778A CA 2760778 A1 CA2760778 A1 CA 2760778A1
Authority
CA
Canada
Prior art keywords
pyrazol
methyl
amino
alkylene
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2760778A
Other languages
English (en)
Inventor
Christiane Bode
Alessandro Boezio
Alan C. Cheng
Deborah Choquette
James R. Coats
Katrina W. Copeland
Hongbing Huang
Daniel La
Richard Lewis
Hongyu Liao
Michele Potashman
John Stellwagen
Shuyan Yi
Mark H. Norman
Markian Stec
Emily A. Peterson
Russell Graceffa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2760778A1 publication Critical patent/CA2760778A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2760778A 2009-05-13 2010-05-12 Composes heteroaryle en tant qu'inhibiteurs des pikk Abandoned CA2760778A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17782509P 2009-05-13 2009-05-13
US61/177,825 2009-05-13
PCT/US2010/034596 WO2010132598A1 (fr) 2009-05-13 2010-05-12 Composés hétéroaryle en tant qu'inhibiteurs des pikk

Publications (1)

Publication Number Publication Date
CA2760778A1 true CA2760778A1 (fr) 2010-11-18

Family

ID=42470855

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760778A Abandoned CA2760778A1 (fr) 2009-05-13 2010-05-12 Composes heteroaryle en tant qu'inhibiteurs des pikk

Country Status (7)

Country Link
US (1) US20120190666A1 (fr)
EP (1) EP2430013B1 (fr)
JP (1) JP2012526836A (fr)
AU (1) AU2010249040B2 (fr)
CA (1) CA2760778A1 (fr)
MX (1) MX2011012037A (fr)
WO (1) WO2010132598A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
WO2009155121A2 (fr) 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021696A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et leurs utilisations
CN103237450A (zh) 2010-10-13 2013-08-07 米伦纽姆医药公司 杂芳基化合物和其用途
CA2824197C (fr) * 2011-01-10 2020-02-25 Michael Martin Procedes de preparation d'isoquinolinones et de formes solides d'isoquinolinones
JP5808826B2 (ja) * 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
TW201331194A (zh) * 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
ES2668279T3 (es) * 2012-03-15 2018-05-17 Signal Pharmaceuticals, Llc Tratamiento del cáncer con inhibidores de la cinasa TOR
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CA2901696C (fr) 2013-02-19 2021-04-13 Amgen Inc. Cis-morpholinone et autres composes servant d'inhibiteurs de mdm2 pour le traitement du cancer
EP2970237B1 (fr) 2013-03-14 2017-09-27 Amgen Inc. Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer
CA2907912A1 (fr) * 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag Pyrimidines a substitution heterocycloalkyle liees a c et leurs utilisations
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
HUE059351T2 (hu) 2013-11-11 2022-11-28 Amgen Inc MDM2 inhibitort és egy vagy több további gyógyszerhatóanyagot tartalmazó kombinációs terápia rákbetegségek kezelésére
DK3157916T3 (en) 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
WO2018013430A2 (fr) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Composés hétérocycliques pour le traitement d'une infection à arenavirus
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP4141005B1 (fr) 2017-09-08 2024-04-03 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP2021523208A (ja) 2018-05-14 2021-09-02 アリアド ファーマシューティカルズ， インコーポレイテッド ピリミジン誘導体の医薬塩及び障害の処置方法
CA3100390A1 (fr) 2018-06-12 2020-03-12 Amgen Inc. Inhibiteurs de kras g12c regroupant un cycle de piperazine et utilisation dans le traitement du cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN111925366B (zh) * 2019-05-13 2024-04-09 广东阿格蕾雅光电材料有限公司 一种咪唑并氮杂环化合物及其应用
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
CN118834208A (zh) 2019-05-21 2024-10-25 美国安进公司 固态形式
KR20220041133A (ko) * 2019-07-24 2022-03-31 메르크 파텐트 게엠베하 4-(이미다조[1,2-a]피리딘-3-일)-피리미딘 유도체
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021098777A1 (fr) * 2019-11-21 2021-05-27 Beigene, Ltd. Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des inhibiteurs de pi3 kinase delta
WO2021126816A1 (fr) 2019-12-16 2021-06-24 Amgen Inc. Schéma posologique d'un inhibiteur du kras g12c
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂
WO2023009475A1 (fr) * 2021-07-26 2023-02-02 President And Fellows Of Harvard College Inhibiteurs de rock2 et leurs utilisations
JP2024529453A (ja) * 2021-07-30 2024-08-06 チルドレンズ ホスピタル メディカル センター 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
NL1010576C2 (nl) * 1998-11-17 2000-05-18 Skf Eng & Res Centre Bv Schroefactuator, omvattende een multifunctionele huls, alsmede een klauw.
CA2620425A1 (fr) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Derives d'anilinopyrazole utilises dans le traitement du diabete
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2009535388A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用
WO2008042639A1 (fr) * 2006-10-02 2008-04-10 Irm Llc Composés et compositions utilisés en tant qu'inhibiteurs de protéine kinase
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
US8367662B2 (en) * 2007-10-17 2013-02-05 Novartis Ag Organic compounds
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
MX2011008674A (es) * 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.

Also Published As

Publication number Publication date
US20120190666A1 (en) 2012-07-26
AU2010249040B2 (en) 2013-08-22
MX2011012037A (es) 2012-02-28
EP2430013A1 (fr) 2012-03-21
EP2430013B1 (fr) 2014-10-15
AU2010249040A1 (en) 2011-12-01
WO2010132598A1 (fr) 2010-11-18
JP2012526836A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
AU2010249040B2 (en) Heteroaryl compounds as PIKK inhibitors
AU2010241723B2 (en) Inhibitors of PI3 kinase and / or mTOR
JP5520831B2 (ja) Ｐｉ３キナーゼの阻害薬
EP2307400B1 (fr) Inhibiteurs de la pi3 kinase
US8729074B2 (en) Inhibitors of PI3 kinase
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
KR20130094710A (ko) Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
KR20110046514A (ko) 피리미딘 화합물, 조성물 및 사용 방법
AU2015201991A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160512